{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:11:37Z","timestamp":1791756697184,"version":"4.3.4"},"reference-count":304,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust Strategic Award","doi-asserted-by":"publisher","award":["097377"],"award-info":[{"award-number":["097377"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MRC Centre for Medical Mycology","award":["MR\/N006364\/1"],"award-info":[{"award-number":["MR\/N006364\/1"]}]},{"DOI":"10.13039\/501100001704","name":"European Society of Clinical Microbiology and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.cmi.2019.05.019","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T20:02:48Z","timestamp":1559332968000},"page":"1096-1113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":169,"title":["ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children"],"prefix":"10.1016","volume":"25","author":[{"given":"A.","family":"Warris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lehrnbecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Roilides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Castagnola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.M.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.05.019_bib1","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/j.1469-0691.2010.03288.x","article-title":"Epidemiology of invasive fungal infections in neonates and children","volume":"16","author":"Steinbach","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.019_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1469-0691.2010.03289.x","article-title":"Invasive fungal infections in congenital immunodeficiencies","volume":"16","author":"Antachopoulos","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.019_bib3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/1469-0691.12800","article-title":"Host genetics and opportunistic fungal infections","volume":"20","author":"Pana","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.019_bib4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/myc.12576","article-title":"Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-\u03b1) inhibitors","volume":"60","author":"Tragiannidis","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib5","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3899\/jrheum.150142","article-title":"A multicenter study of invasive fungal infections in patients with childhood-onset systemic lupus erythematosus","volume":"42","author":"Silva","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cmi.2019.05.019_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1542\/peds.2005-1161","article-title":"Epidemiology, outcomes, and costs of IA in immunocompromised children in the united states, 2000","volume":"117","author":"Zaoutis","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.cmi.2019.05.019_bib7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/pix046","article-title":"Epidemiology of Invasive Fungal Disease in Children","volume":"6","author":"Pana","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.cmi.2019.05.019_bib8","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/sj.bmt.1702654","article-title":"Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years","volume":"26","author":"Hovi","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00006454-200203000-00013","article-title":"Infections diagnosed in the first year after pediatric stem cell transplantation","volume":"21","author":"Benjamin","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00006454-199308000-00009","article-title":"Invasive Aspergillus infections in a pediatric hospital: a ten year review","volume":"12","author":"Walmsley","year":"1993","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib12","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1086\/313445","article-title":"Aspergillosis in children with cancer: a 34-year experience","volume":"29","author":"Abbasi","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1439-0507.1999.00496.x","article-title":"Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival","volume":"42","author":"Groll","year":"1999","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib14","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.1542\/peds.2007-2117","article-title":"Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases","volume":"121","author":"Burgos","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.cmi.2019.05.019_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jpids\/piu074","article-title":"A prospective, international cohort study of invasive mold infection in children","volume":"4","author":"Wattier","year":"2015","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.cmi.2019.05.019_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/jof2020015","article-title":"Aspergillosis in granulomatous disease","volume":"2","author":"King","year":"2016","journal-title":"J Fungi"},{"key":"10.1016\/j.cmi.2019.05.019_bib17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1086\/514717","article-title":"Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life","volume":"27","author":"Groll","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mmcr.2014.02.001","article-title":"Screening of the central nervous system in children with invasive pulmonary aspergillosis","volume":"4","author":"Broenen","year":"2014","journal-title":"Med Mycol Case Rep"},{"key":"10.1016\/j.cmi.2019.05.019_bib19","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/clinids\/22.6.1102","article-title":"Primary cutaneous aspergillosis in neonates: case report and review","volume":"22","author":"Papouli","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/INF.0b013e3181f13b23","article-title":"Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France","volume":"30","author":"Beaut\u00e9","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib21","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1093\/cid\/cir731","article-title":"Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey","volume":"53","author":"Blumental","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4614-4726-9_3","article-title":"Invasive fungal infections in patients with chronic granulomatous disease","volume":"764","author":"Henriet","year":"2013","journal-title":"Adv Exp Med Biol"},{"issue":"Suppl 7","key":"10.1016\/j.cmi.2019.05.019_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID guideline for the diagnosis and management of candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp","volume":"18","author":"Hope","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.cmi.2019.05.019_bib24","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European conference on infections in leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2019.05.019_bib25","first-page":"e1","article-title":"Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Micobiol Infect"},{"issue":"Suppl 7","key":"10.1016\/j.cmi.2019.05.019_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12037","article-title":"ESCMID Diagnostic and management guideline for candida diseases 2012: developing european guidelines in clinical microbiology and infectious diseases","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.019_bib27","unstructured":"European Medicines Agency. ICH topic E 11 clinical investigation of medicinal products in the paediatric population. Note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP\/ICH\/2711\/99). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientifi c_guideline\/2009\/09\/WC500002926.pdf (accessed Aug 10, 2018)."},{"key":"10.1016\/j.cmi.2019.05.019_bib28","unstructured":"European Community. Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation (EC) No 726\/2004 https:\/\/ec.europa.eu\/health\/human-use\/paediatric-medicines\/developments\/2016_pc_report_2017_en (accessed Aug 10, 2018)."},{"key":"10.1016\/j.cmi.2019.05.019_bib29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jpids\/pix030","article-title":"Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: A Systematic Review","volume":"7","author":"Fisher","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.cmi.2019.05.019_bib30","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2014.03.026","article-title":"Role of acute graft versus-host disease in the risk of bacteremia and invasive fungal disease after allogeneic hemopoietic stem cell transplantation in children. Results from a single-center observational study","volume":"20","author":"Castagnola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2012.08.012","article-title":"Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Srinivasan","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1439-0507.2007.01449.x","article-title":"Invasive aspergillosis in a paediatric haematology department: a 15-year review","volume":"51","author":"Crassard","year":"2008","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/ejh.12910","article-title":"Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric oncohematological patients","volume":"99","author":"Cesaro","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cmi.2019.05.019_bib34","first-page":"560","article-title":"Invasive fungal infections in paediatric acute myeloid leukaemia","volume":"37","author":"Ducassou","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.cmi.2019.05.019_bib35","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1600-0609.2012.01770.x","article-title":"Epidemiology of infections in children with acquired aplastic anaemia: a retrospective multicenter study in Italy","volume":"88","author":"Quarello","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cmi.2019.05.019_bib36","article-title":"Invasive fungal disease in pediatric solid organ transplant recipients","author":"Saxena","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.cmi.2019.05.019_bib37","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-138-9-200305060-00006","article-title":"Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial","volume":"138","author":"Winston","year":"2003","journal-title":"Annals of internal medicine"},{"key":"10.1016\/j.cmi.2019.05.019_bib38","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2019.05.019_bib39","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2019.05.019_bib40","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2019.05.019_bib41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2010.04.017","article-title":"Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients","volume":"17","author":"Winston","year":"2011","journal-title":"Biology of blood and marrow transplantation : Journal of the American Society for Blood and Marrow Transplantation"},{"key":"10.1016\/j.cmi.2019.05.019_bib42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12879-015-0855-6","article-title":"Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"15","author":"Bow","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2019.05.019_bib44","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. Fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl 7","key":"10.1016\/j.cmi.2019.05.019_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12660","article-title":"Invasive fungal infections in solid organ transplant recipients","volume":"20","author":"Gavalda","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.019_bib46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-3062.2006.00156.x","article-title":"Variation in antifungal prophylaxis strategies in lung transplantation","volume":"8","author":"Husain","year":"2006","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib47","first-page":"269","article-title":"Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance\u00ae registry analysis","volume":"55","author":"Husain","year":"2017","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2019.05.019_bib48","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/petr.12263","article-title":"International Pediatric Lung Transplant Collaborative (IPLTC). Antifungal prophylaxis in pediatric lung transplantation: an international multicenter survey","volume":"18","author":"Mead","year":"2014","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1399-3062.2004.00047.x","article-title":"Nosocomial invasive aspergillosis in a heart transplant patient acquired during a break in the hepa air filtration system","volume":"6","author":"Munoz","year":"2004","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib50","doi-asserted-by":"crossref","first-page":"E454","DOI":"10.1111\/ctr.12129","article-title":"Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era","volume":"27","author":"Saliba","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib51","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/cid\/ciu1128","volume":"60","author":"Saliba","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.12659\/AOT.881989","article-title":"Invasive fungal infections following liver transplantation - risk factors, incidence and outcome","volume":"16","author":"Pacholczyk","year":"2011","journal-title":"Ann Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib53","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1399-3046.2007.00754.x","article-title":"Aspergillosis in children after liver transplantation: single center experience","volume":"11","author":"Teisseyre","year":"2007","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib54","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa021931","article-title":"Itraconazole to prevent fungal infections in chronic granulomatous disease","volume":"348","author":"Gallin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2019.05.019_bib55","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/515129","volume":"28","author":"Menichetti","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib56","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1128\/AAC.44.7.1887-1893.2000","article-title":"Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin b","volume":"44","author":"Harousseau","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib57","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1439-0507.1999.00518.x","article-title":"Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-\u00df-cyclodextrin oral solution or coated-pellet capsules","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib58","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1128\/AAC.46.8.2554-2563.2002","article-title":"Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis","volume":"46","author":"Groll","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib59","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1128\/AAC.42.2.404","article-title":"Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children","volume":"42","author":"de Repentigny","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib60","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bmt.1702023","article-title":"Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders","volume":"24","author":"Foot","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib61","first-page":"213","article-title":"Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants","volume":"15","author":"Simon","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cmi.2019.05.019_bib62","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2165\/00003088-200645110-00004","article-title":"Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients","volume":"45","author":"Hennig","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2019.05.019_bib63","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1128\/AAC.00297-07","article-title":"Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents","volume":"51","author":"Abdel-Rahman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib64","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2011.051995","article-title":"Comparative clinical effectiveness of prophylactic voriconazole\/posaconazole to fluconazole\/itraconazole in patients with acute myeloid leukemia\/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period","volume":"97","author":"Ananda-Rajah","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2019.05.019_bib65","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure--response of posaconazole used for prophylaxis against invasive fungal infections: Evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.cmi.2019.05.019_bib66","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jac\/dkv380","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib67","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","article-title":"Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2019.05.019_bib68","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/INF.0b013e3182195808","article-title":"A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease","volume":"30","author":"Welzen","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib69","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1471-2334-12-263","article-title":"Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation","volume":"12","author":"D\u00f6ring","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib70","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10096-010-0957-4","article-title":"Posaconazole salvage treatment in paediatric patients: A multicentre survey","volume":"29","author":"Lehrnbecher","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib71","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/jac\/dkt438","article-title":"Azole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal audit","volume":"69","author":"Yunus","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/mmy\/myv087","article-title":"Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation","volume":"54","author":"Heinz","year":"2016","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2019.05.019_bib73","first-page":"375","article-title":"Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia","volume":"55","author":"D\u00f6ring","year":"2017","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2019.05.019_bib74","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/INF.0000000000000963","article-title":"Pharmacokinetics of posaconazole oral suspension in children dosed according to body surface area","volume":"35","author":"Vanstraelen","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib75","first-page":"19","article-title":"Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome","volume":"19","author":"Mattiuzzi","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cmi.2019.05.019_bib76","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.23388","article-title":"The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole","volume":"88","author":"Barreto","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2019.05.019_bib77","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib78","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib79","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib80","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib81","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1128\/AAC.00896-10","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib82","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.00751-08","article-title":"Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies","volume":"53","author":"Karlsson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib83","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1128\/AAC.05010-11","article-title":"Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults","volume":"55","author":"Driscoll","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib84","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.1128\/AAC.00531-11","article-title":"Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults","volume":"55","author":"Driscoll","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib85","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib86","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/jac\/dks258","article-title":"Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients","volume":"67","author":"Pieper","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib87","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/bmt.2011.111","article-title":"Voriconazole as primary antifungal prophylaxis in children undergoing allo-sct","volume":"47","author":"Molina","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib88","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/INF.0000000000001339","article-title":"Safety, Efficacy, and exposure-response of voriconazole in pediatric patients with invasive aspergillosis, invasive candidiasis or esophageal candidiasis","volume":"36","author":"Martin","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib89","first-page":"577","article-title":"Randomized double-blind study of liposomal amphotericin b (ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients","volume":"12","author":"Tollemar","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib90","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bmt.1701543","article-title":"Liposomal amphotericin (ambisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study","volume":"23","author":"Kelsey","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib91","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/annonc\/mdl128","article-title":"Low-dose liposomal amphotericin b in the prevention of invasive fungal infections in patients with prolonged neutropenia: Results from a randomized, single-center trial","volume":"17","author":"Penack","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2019.05.019_bib92","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/jac\/dkx133","article-title":"Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl B","key":"10.1016\/j.cmi.2019.05.019_bib93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/28.suppl_B.73","article-title":"Efficacy of amphotericin b encapsulated in liposomes (ambisome) in the treatment of invasive fungal infections in immunocompromised patients","volume":"28","author":"Ringden","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib94","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.50.3.935-942.2006","article-title":"Population pharmacokinetics of liposomal amphotericin b in pediatric patients with malignant diseases","volume":"50","author":"Hong","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib95","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jac\/dkp196","article-title":"Safety, tolerance and outcome of treatment with liposomal amphotericin b in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation","volume":"64","author":"Kolve","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib96","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1469-0691.2011.03483.x","article-title":"Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients","volume":"17","author":"Bochennek","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.019_bib97","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/INF.0000000000000335","article-title":"Safety and tolerability of high-dose weekly liposomal amphotericin B antifungal prophylaxis","volume":"33","author":"Hand","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib98","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1128\/AAC.01427-16","article-title":"Population pharmacokinetics of liposomal amphotericin B in immunocompromised children","volume":"60","author":"Lestner","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib99","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01477-16","article-title":"Safety, tolerability, and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients","volume":"61","author":"Seibel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib100","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib101","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.bbmt.2012.03.014","article-title":"Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant","volume":"18","author":"Huang","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.cmi.2019.05.019_bib102","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/AAC.49.8.3317-3324.2005","article-title":"Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients","volume":"49","author":"Seibel","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib103","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1128\/AAC.00398-07","article-title":"Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing","volume":"51","author":"Hope","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib104","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1097\/INF.0b013e3182127eaf","article-title":"Safety of micafungin in pediatric clinical trials","volume":"30","author":"Arrieta","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib105","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.bbmt.2010.05.002","article-title":"Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: A pharmacokinetic study","volume":"16","author":"Mehta","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.cmi.2019.05.019_bib106","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1097\/INF.0b013e31829efd14","article-title":"Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis","volume":"32","author":"Benjamin","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib107","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bmt.2014.136","article-title":"Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT","volume":"49","author":"Park","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib108","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/jac\/dku544","article-title":"Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease","volume":"70","author":"Bochennek","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib109","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/MPH.0000000000000218","article-title":"Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation","volume":"37","author":"Albano","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.cmi.2019.05.019_bib110","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/AAC.03736-14","article-title":"Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents","volume":"59","author":"Hope","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib111","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin b for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib112","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.50.1.143-147.2006","article-title":"Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies","volume":"50","author":"Mattiuzzi","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib113","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1093\/jac\/dkr271","article-title":"A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study)","volume":"66","author":"Cattaneo","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib114","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/AAC.49.11.4536-4545.2005","article-title":"Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents","volume":"49","author":"Walsh","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib115","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1128\/AAC.01027-08","article-title":"Pharmacokinetics and safety of caspofungin in older infants and toddlers","volume":"53","author":"Neely","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib116","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/INF.0b013e3181af5a15","article-title":"Safety experience with caspofungin in pediatric patients","volume":"28","author":"Zaoutis","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib117","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1128\/AAC.00905-10","article-title":"Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients","volume":"55","author":"Li","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib118","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2334-12-151","article-title":"Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"12","author":"D\u00f6ring","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib119","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s11095-014-1595-9","article-title":"Physiology-based pharmacokinetics of caspofungin for adults and paediatrics","volume":"32","author":"Stader","year":"2015","journal-title":"Pharm Res"},{"key":"10.1016\/j.cmi.2019.05.019_bib120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coph.2015.07.002","article-title":"Drug-interaction of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice","volume":"24","author":"Lempers","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.cmi.2019.05.019_bib121","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12751","article-title":"Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4","author":"Groll","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib122","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/pbc.22972","article-title":"Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma","volume":"57","author":"Pana","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.cmi.2019.05.019_bib123","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/jac\/dkr223","article-title":"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia","volume":"66","author":"van Schie","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib124","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","article-title":"Adverse interactions between antifungal azoles and vincristine: review and analysis of cases","volume":"55","author":"Moriyama","year":"2012","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib125","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.healun.2009.11.603","article-title":"Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin b for aspergillus infection prevention in lung transplantation","volume":"29","author":"Monforte","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib126","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2006.01548.x","article-title":"Voriconazole prophylaxis in lung transplant recipients","volume":"6","author":"Husain","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib127","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1016\/j.transproceed.2005.10.043","article-title":"Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin b as prophylaxis of fungal infections in high-risk liver transplant recipients","volume":"37","author":"Castroagudin","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cmi.2019.05.019_bib128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/TP.0b013e3181932e76","article-title":"Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients","volume":"87","author":"Fortun","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2019.05.019_bib129","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0022-3476(05)82023-2","article-title":"Long-term itraconazole prophylaxis against aspergillus infections in thirty-two patients with chronic granulomatous disease","volume":"125","author":"Mouy","year":"1994","journal-title":"J Pediatr"},{"key":"10.1016\/j.cmi.2019.05.019_bib130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJM199102213240801","article-title":"A controlled trial of interferon to prevent infection in chronic granulomatous disease","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2019.05.019_bib131","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/S0090-1229(05)80044-3","article-title":"Interferon- in the treatment of the chronic granulomatous diseases of childhood","volume":"61","author":"Gallin","year":"1991","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.cmi.2019.05.019_bib132","first-page":"295","article-title":"Recombinant human interferon- in patients with chronic granulomatous disease\u2013European follow up study","volume":"154","author":"Weening","year":"1995","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.cmi.2019.05.019_bib133","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/422993","article-title":"Long-term interferon-gamma therapy for patients with chronic granulomatous disease","volume":"39","author":"Marciano","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib134","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":"Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib135","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000083447","article-title":"Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin b","volume":"113","author":"Kruger","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.cmi.2019.05.019_bib136","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bmt.1705720","article-title":"Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and\/or systemic fungal infection","volume":"40","author":"de Fabritiis","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib137","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/jac\/dkm521","article-title":"Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients","volume":"61","author":"Allinson","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib138","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2009.020073","article-title":"Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: Results of the vosifi study","volume":"95","author":"Cordonnier","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2019.05.019_bib139","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/tid.12068","article-title":"Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients","volume":"15","author":"Liu","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02013825","article-title":"Ct of invasive pulmonary aspergillosis in children with cancer","volume":"23","author":"Taccone","year":"1993","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.cmi.2019.05.019_bib141","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00006454-200101000-00002","article-title":"Computed tomography in the evaluation of febrile neutropenic pediatric oncology patients","volume":"20","author":"Archibald","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib142","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1997.15.1.139","article-title":"Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery","volume":"15","author":"Caillot","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cmi.2019.05.019_bib143","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2214\/ajr.169.5.9353456","article-title":"Early detection of pneumonia in febrile neutropenic patients: Use of thin-section ct","volume":"169","author":"Heussel","year":"1997","journal-title":"AJR American journal of roentgenology"},{"key":"10.1016\/j.cmi.2019.05.019_bib144","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.2001.19.1.253","article-title":"Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia","volume":"19","author":"Caillot","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cmi.2019.05.019_bib145","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/INF.0b013e3180616cbb","article-title":"Prospective aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients","volume":"26","author":"Steinbach","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib146","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/pbc.20717","article-title":"Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders","volume":"48","author":"Hovi","year":"2007","journal-title":"Pediatric blood & cancer"},{"key":"10.1016\/j.cmi.2019.05.019_bib147","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/INF.0b013e31817197ab","article-title":"Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis","volume":"27","author":"Hayden","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib148","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1469-0691.2009.03065.x","article-title":"Performance of the galactomannan antigen detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing haemopoietic stem cell transplantation","volume":"16","author":"Castagnola","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.019_bib149","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jpids\/pis044","article-title":"Galactomannan antigen testing for diagnosis of invasive aspergillosis in pediatric hematology patients","volume":"1","author":"Fisher","year":"2012","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.cmi.2019.05.019_bib150","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/myc.12048","article-title":"Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies","volume":"56","author":"Jha","year":"2013","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib151","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/pbc.24363","article-title":"Aspergillus galactomannan antigen assay and invasive aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients","volume":"60","author":"Choi","year":"2013","journal-title":"Pediatric blood & cancer"},{"key":"10.1016\/j.cmi.2019.05.019_bib152","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jmii.2013.12.003","article-title":"Threshold of galactomannan antigenemia positivity for early diagnosis of invasive aspergillosis in neutropenic children","volume":"49","author":"Dinand","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.cmi.2019.05.019_bib153","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/cid\/ciw592","article-title":"Galactomannan, \u03b2-D-glucan, and polymerase chain reaction-based assays for the diagnosis of invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"63","author":"Lehrnbecher","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib154","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1128\/JCM.01682-16","article-title":"Prospective biomarker screening for diagnosis of invasive aspergillosis in high-risk pediatric patients","volume":"55","author":"Loeffler","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2019.05.019_bib155","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12281-017-0274-9","article-title":"Progress in the diagnosis of invasive fungal disease in children","volume":"11","author":"Warris","year":"2017","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.cmi.2019.05.019_bib156","doi-asserted-by":"crossref","first-page":"1000.e4","DOI":"10.1016\/j.cmi.2017.05.006","article-title":"The misleading effect of serum galactomannan testing in high-risk haematology patients receiving prophylaxis with micafungin","volume":"23","author":"Vena","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.05.019_bib157","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/cid\/ciq206","article-title":"\u00df-d-glucan assay for the diagnosis of invasive fungal infections: A meta-analysis","volume":"52","author":"Karageorgopoulos","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib158","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/cid\/cir897","article-title":"\u00df-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: A systematic review and meta-analysis of cohort studies from the third european conference on infections in leukemia (ecil-3)","volume":"54","author":"Lamoth","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib159","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1128\/CVI.00025-07","article-title":"Quantification of 1,3-beta-d-glucan levels in children: Preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting","volume":"14","author":"Smith","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.cmi.2019.05.019_bib160","first-page":"905","article-title":"Value of plasma beta-glucan in early diagnosis of invasive fungal infection in children","volume":"11","author":"Zhao","year":"2009","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"10.1016\/j.cmi.2019.05.019_bib161","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1128\/CVI.00038-10","article-title":"High levels of beta-d-glucan in immunocompromised children with proven invasive fungal disease","volume":"17","author":"Mularoni","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.cmi.2019.05.019_bib162","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3855\/jidc.2110","article-title":"Diagnostic potential of nested pcr, galactomannan eia, and beta-d-glucan for invasive aspergillosis in pediatric patients","volume":"6","author":"Badiee","year":"2012","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.cmi.2019.05.019_bib163","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2016.07.007","article-title":"Detection of \u03b2-D-glucan for the diagnosis of invasive fungal infection in children with hematological malignancy","volume":"73","author":"Guitard","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2019.05.019_bib164","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/myc.12584","article-title":"Comparative evaluation of pan-fungal real-time PCR, galactomannan and (1-3)-\u03b2-D-glucan assay for invasive fungal infection in paediatric cancer patients","volume":"60","author":"Gupta","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib165","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1365-2141.2003.04308.x","article-title":"Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis","volume":"121","author":"Becker","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2019.05.019_bib166","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1128\/JCM.00077-07","article-title":"Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients","volume":"45","author":"Clancy","year":"2007","journal-title":"Journal of clinical microbiology"},{"key":"10.1016\/j.cmi.2019.05.019_bib167","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1097\/01.tp.0000263992.41003.33","article-title":"Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients","volume":"83","author":"Husain","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2019.05.019_bib168","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1086\/647935","article-title":"Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases","volume":"49","author":"Maertens","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib169","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2334-10-44","article-title":"Galactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematology patients","volume":"10","author":"Hsu","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib170","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1378\/chest.09-0701","article-title":"Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies","volume":"137","author":"Bergeron","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2019.05.019_bib171","first-page":"528","article-title":"Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis","volume":"55","author":"Eigl","year":"2017","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2019.05.019_bib172","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/INF.0b013e31818f0934","article-title":"The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis","volume":"28","author":"Desai","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib173","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ppul.22670","article-title":"Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan","volume":"48","author":"de Mol","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.cmi.2019.05.019_bib174","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1128\/JCM.37.4.1186-1189.1999","article-title":"Aspergillus meningitis: Diagnosis by non-culture-based microbiological methods and management","volume":"37","author":"Verweij","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2019.05.019_bib175","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1128\/JCM.40.4.1496-1499.2002","article-title":"Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis","volume":"40","author":"Viscoli","year":"2002","journal-title":"Journal of clinical microbiology"},{"key":"10.1016\/j.cmi.2019.05.019_bib176","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00467-003-1113-5","article-title":"Cerebral aspergillosis in an infant with corticosteroid-resistant nephrotic syndrome","volume":"18","author":"Roilides","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.cmi.2019.05.019_bib177","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1034\/j.1399-3062.2000.020307.x","article-title":"Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole","volume":"2","author":"Machetti","year":"2000","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib178","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056706","article-title":"Diagnostic performance of an Aspergillus-specific nested PCR assay in cerebrospinal fluid samples of immunocompromised patients for detection of central nervous system aspergillosis","volume":"8","author":"Reinwald","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2019.05.019_bib179","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7182\/pit2013386","article-title":"Aspergillus galactomannan antigen for diagnosis and treatment monitoring in cerebral aspergillosis","volume":"23","author":"Soeffker","year":"2013","journal-title":"Prog Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib180","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1128\/JCM.00747-15","article-title":"\u03b2-D-Glucan screening for detection of invasive fungal disease in children undergoing allogeneic hematopoietic stem cell transplantation","volume":"53","author":"Koltze","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2019.05.019_bib181","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/myc.12664","article-title":"Performance of 1,3-\u03b2-D-glucan for diagnosing invasive fungal diseases in children","volume":"60","author":"Calitri","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib182","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/cid\/civ154","article-title":"High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies","volume":"60","author":"Stanzani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib183","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1086\/521245","article-title":"The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients","volume":"45","author":"Lass-Fl\u0151rl","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib184","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1399-3046.2007.00733.x","article-title":"Invasive diagnostic procedures for pulmonary infiltrates in pediatric hematopoietic stem cell transplant recipients","volume":"11","author":"Armenian","year":"2007","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib185","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/myc.12319","article-title":"Our 2015 approach to invasive pulmonary aspergillosis","volume":"58","author":"Liss","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib186","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1309\/AJCPEMVYT88AVFKG","article-title":"Positive impact of fungal histopathology on immunocompromised pediatric patients with histology-proven invasive fungal infection","volume":"144","author":"Dekio","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cmi.2019.05.019_bib187","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1128\/JCM.43.8.3925-3931.2005","article-title":"Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity","volume":"43","author":"Mennink-Kersten","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2019.05.019_bib188","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/14767058.2012.722716","article-title":"(1-3)-beta-D-glucan levels in candidiasis infections in the critically ill neonate","volume":"26","author":"Goudjil","year":"2013","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.cmi.2019.05.019_bib189","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/MPH.0b013e3181b83e77","article-title":"Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients","volume":"31","author":"Armenian","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.cmi.2019.05.019_bib190","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/13693780600939955","article-title":"Evaluation of pan-fungal PCR assay and aspergillus antigen detection in the diagnosis of invasive fungal infections in high risk paediatric cancer patients","volume":"44","author":"El-Mahallawy","year":"2006","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2019.05.019_bib191","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1439-0507.2008.01512.x","article-title":"Assessment of the lightcycler PCR assay for diagnosis of invasive aspergillosis in paediatric patients with onco-haematological diseases","volume":"51","author":"Cesaro","year":"2008","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib192","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1099\/jmm.0.007393-0","article-title":"Detection of aspergillus DNA by a nested PCR assay is able to improve the diagnosis of invasive aspergillosis in paediatric patients","volume":"58","author":"Hummel","year":"2009","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.cmi.2019.05.019_bib193","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2010.209","article-title":"Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients","volume":"24","author":"Landlinger","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2019.05.019_bib194","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1439-0507.2011.02157.x","article-title":"Diagnosis of invasive fungal infections using real-time PCR assay in paediatric acute leukaemia induction","volume":"55","author":"Mandhaniya","year":"2012","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib195","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/myc.12192","article-title":"Assessment of aspergillus-specific PCR as a screening method for invasive aspergillosis in paediatric cancer patients and allogeneic haematopoietic stem cell recipients with suspected infections","volume":"57","author":"Reinwald","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib196","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin b for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2019.05.019_bib197","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (secure): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2019.05.019_bib198","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib199","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s10096-003-0960-0","article-title":"Voriconazole in the treatment of invasive mold infections in transplant recipients","volume":"22","author":"Fortun","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib200","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.healun.2003.10.014","article-title":"Superiority of voriconazole over amphotericin b in the treatment of invasive aspergillosis after heart transplantation","volume":"24","author":"Wieland","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib201","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.transproceed.2007.05.012","article-title":"Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients","volume":"39","author":"Veroux","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cmi.2019.05.019_bib202","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/INF.0b013e31824acc33","article-title":"Therapeutic monitoring of voriconazole in children less than three years of age: A case report and summary of voriconazole concentrations for ten children","volume":"31","author":"Doby","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib203","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jac\/dkr517","article-title":"Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: A prospective study","volume":"67","author":"Soler-Palacin","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib204","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/AAC.01540-12","article-title":"Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients","volume":"57","author":"Bartelink","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib205","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin b as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (ambiload trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib206","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0378-5173(02)00066-2","article-title":"A comparative study of plasma concentrations of liposomal amphotericin b (l-amp-lrc-1) in adults, children and neonates","volume":"238","author":"Kotwani","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1016\/j.cmi.2019.05.019_bib207","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01477-16","article-title":"Safety, tolerability, and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients","volume":"61","author":"Seibel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib208","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1128\/AAC.00425-10","article-title":"Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin b, and the combination of bot,h in allogeneic hematopoietic stem cell recipients","volume":"54","author":"Groll","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib209","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s10156-011-0357-4","article-title":"Evaluation of the safety and efficacy of liposomal amphotericin b (l-amb) in children","volume":"18","author":"Sunakawa","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib210","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: An european organisation for research and treatment of cancer study","volume":"45","author":"Herbrecht","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib211","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib212","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/AAC.05134-11","article-title":"Phase II dose escalation study of caspofungin for invasive aspergillosis","volume":"55","author":"Cornely","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2007.10.002","article-title":"Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation","volume":"27","author":"Groetzner","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib214","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1399-3062.2009.00490.x","article-title":"Caspofungin for post solid organ transplant invasive fungal disease: Results of a retrospective observational study","volume":"12","author":"Winkler","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib215","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1471-2334-10-182","article-title":"Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: Results of a prospective observational registry","volume":"10","author":"Maertens","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib216","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2334-7-28","article-title":"Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients","volume":"7","author":"Cesaro","year":"2007","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib217","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/INF.0b013e3181af5a15","article-title":"Safety experience with caspofungin in pediatric patients","volume":"28","author":"Zaoutis","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib218","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1542\/peds.2008-1158","article-title":"A prospective, multicenter study of caspofungin for the treatment of documented candida or aspergillus infections in pediatric patients","volume":"123","author":"Zaoutis","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.cmi.2019.05.019_bib219","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ijantimicag.2011.07.008","article-title":"Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: A brief report","volume":"38","author":"Ngai","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.05.019_bib220","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jac\/dkl009","article-title":"Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey","volume":"57","author":"Groll","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib221","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.23109","article-title":"Liposomal amphotericin b in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: A randomized pilot study (combistrat trial)","volume":"110","author":"Caillot","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2019.05.019_bib222","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/myc.12161","article-title":"Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study","volume":"57","author":"Candoni","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib223","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: A randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Annals of internal medicine"},{"key":"10.1016\/j.cmi.2019.05.019_bib224","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.tp.0000202421.94822.f7","article-title":"Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study","volume":"81","author":"Singh","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2019.05.019_bib225","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2014.08.012","article-title":"Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies","volume":"45","author":"Raad","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.05.019_bib226","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin b lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2019.05.019_bib227","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1080\/13693780400025237","article-title":"Aspergillosis in the clear outcomes trial: Working toward a real-world clinical perspective","volume":"43","author":"Kleinberg","year":"2005","journal-title":"Medical mycology"},{"issue":"Suppl 6","key":"10.1016\/j.cmi.2019.05.019_bib228","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1086\/429329","article-title":"Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry","volume":"40","author":"Pappas","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib229","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1128\/AAC.41.9.1944","article-title":"Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis","volume":"41","author":"Walsh","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib230","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00006454-199908000-00010","article-title":"Amphotericin B lipid complex in pediatric patients with invasive fungal infections","volume":"18","author":"Walsh","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib231","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s100960000437","article-title":"Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients","volume":"20","author":"Herbrecht","year":"2001","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib232","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.inf.0000153183.51258.b8","article-title":"Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections","volume":"24","author":"Wiley","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib233","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0002-9343(94)90023-X","article-title":"Niaid mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis","volume":"97","author":"Denning","year":"1994","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2019.05.019_bib234","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/323020","article-title":"Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or aids","volume":"33","author":"Caillot","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib235","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1399-3046.2006.00643.x","article-title":"Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy","volume":"11","author":"Grigull","year":"2007","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib236","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40261-015-0297-3","article-title":"Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation","volume":"35","author":"Kim","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cmi.2019.05.019_bib237","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/infdis\/155.4.766","article-title":"Pharmacokinetics of amphotericin B in infants and children","volume":"155","author":"Starke","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib238","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1128\/AAC.33.11.1989","article-title":"Pharmacokinetics of amphotericin B in children","volume":"33","author":"Benson","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib239","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0022-3476(88)80653-X","article-title":"Pharmacokinetics and adverse effects of amphotericin B in infants and children","volume":"113","author":"Koren","year":"1988","journal-title":"J Pediatr"},{"key":"10.1016\/j.cmi.2019.05.019_bib240","first-page":"95","article-title":"Amphotericin B serum levels in pediatric bone marrow transplant recipients","volume":"7","author":"Emminger","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib241","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.0306-5251.2001.01496.x","article-title":"Population pharmacokinetics of amphotericin B in children with malignant diseases","volume":"52","author":"Nath","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2019.05.019_bib242","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized, double-blind clinical trial of amphotericin b colloidal dispersion vs. Amphotericin b in the empirical treatment of fever and neutropenia","volume":"27","author":"White","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib243","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin b colloidal dispersion versus amphotericin b for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib244","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00043426-200005000-00009","article-title":"Use of amphotericin B colloidal dispersion in children","volume":"22","author":"Sandler","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.cmi.2019.05.019_bib245","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3201\/eid1404.071157","article-title":"Emericella quadrilineata as cause of invasive aspergillosis","volume":"14","author":"Verweij","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib246","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1128\/JCM.01509-12","article-title":"Aspergillus tanneri sp. nov., a new pathogen that causes invasive disease refractory to antifungal therapy","volume":"50","author":"Sugui","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2019.05.019_bib247","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/599345","article-title":"Invasive aspergillosis due to Neosartorya udagawae","volume":"49","author":"Vinh","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib248","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00006454-199802000-00013","article-title":"Liposomal amphotericin b treatment for neonatal fungal infections","volume":"17","author":"Scarcella","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib249","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10096-003-0993-4","article-title":"High-dose liposomal amphotericin b in the therapy of systemic candidiasis in neonates","volume":"22","author":"Juster-Reicher","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib250","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.earlhumdev.2012.07.015","article-title":"Is liposomal amphotericin b really safety in neonates?","volume":"89","author":"Karadag-Oncel","year":"2013","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.cmi.2019.05.019_bib251","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.earlhumdev.2012.07.002","article-title":"Response to \"is liposomal amphotericin b really safety in neonates?","volume":"89","author":"Manzoni","year":"2013","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.cmi.2019.05.019_bib252","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e3181af6201","article-title":"Nephrotoxicity associated with amphotericin B deoxycholate in neonates","volume":"28","author":"Le","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib253","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1128\/AAC.49.12.5092-5098.2005","article-title":"Population pharmacokinetics of amphotericin B lipid complex in neonates","volume":"49","author":"W\u00fcrthwein","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib254","first-page":"729","article-title":"Compassionate use of voriconazole in newborn infants diagnosed with severe invasive fungal sepsis","volume":"17","author":"Celik","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.cmi.2019.05.019_bib255","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.inf.0000145408.51526.0a","article-title":"Caspofungin therapy of neonates with invasive candidiasis","volume":"23","author":"Odio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib256","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/01.inf.0000245103.07614.e1","article-title":"The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants","volume":"25","author":"Heresi","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib257","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/INF.0b013e3181910e2d","article-title":"Pharmacokinetics of an elevated dosage of micafungin in premature neonates","volume":"28","author":"Smith","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib258","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/AAC.00868-08","article-title":"Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age","volume":"53","author":"S\u00e1ez-Llorens","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib259","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/AAC.01679-09","article-title":"Population pharmacokinetics of micafungin in neonates and young infants","volume":"54","author":"Hope","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib260","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/clpt.2011.26","article-title":"Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates","volume":"89","author":"Cohen-Wolkowiez","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2019.05.019_bib261","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib262","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12281-015-0224-3","article-title":"Fundament and prerequisites for the application of an antifungal TDM service","volume":"9","author":"Br\u00fcggemann","year":"2015","journal-title":"Current Fungal Infection Reports"},{"key":"10.1016\/j.cmi.2019.05.019_bib263","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40262-014-0139-0","article-title":"Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications","volume":"53","author":"Stockmann","year":"2014","journal-title":"Clinical pharmacokinetics"},{"key":"10.1016\/j.cmi.2019.05.019_bib264","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S1473-3099(17)30316-X","article-title":"The global problem of antifungal resistance: prevalence, mechanisms, and management","volume":"17","author":"Perlin","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drup.2014.06.001","article-title":"The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside","volume":"17","author":"Seyedmousavi","year":"2014","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.cmi.2019.05.019_bib266","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21-22","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.cmi.2019.05.019_bib267","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1200\/JCO.2003.04.052","article-title":"Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients","volume":"21","author":"Glasmacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cmi.2019.05.019_bib268","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1093\/clinids\/9.Supplement_1.S94","article-title":"Ketoconazole vs. Itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary results of two nonrandomized studies","volume":"9","author":"Tricot","year":"1987","journal-title":"Rev Infect Diseases"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2019.05.019_bib269","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1439-0507.1989.tb02299.x","article-title":"Antifungal prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels","volume":"32","author":"Boogaerts","year":"1989","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib270","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1439-0507.1999.00505.x","article-title":"Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2019.05.019_bib271","article-title":"Clinical pharmacokinetics and dose recommendations for posaconazole in infants and children","author":"Boonsathorn","year":"2018","journal-title":"Clinical pharmacokinetics"},{"key":"10.1016\/j.cmi.2019.05.019_bib272","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/jac\/dkx263","article-title":"Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib273","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib274","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib275","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1128\/AAC.00032-15","article-title":"Achieving target voriconazole concentrations more accurately in children and adolescents","volume":"59","author":"Neely","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib276","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/14787210.2016.1207526","article-title":"Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections","volume":"14","author":"Job","year":"2016","journal-title":"Expert review of anti-infective therapy"},{"key":"10.1016\/j.cmi.2019.05.019_bib277","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1093\/jac\/dkw127","article-title":"Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial","volume":"71","author":"Hope","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib278","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1128\/AAC.03023-15","article-title":"Pharmacodynamics of voriconazole in children: further steps along the path to true individualized therapy","volume":"60","author":"Huurneman","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib279","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib280","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib281","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/jac\/dkp397","article-title":"Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin b","volume":"65","author":"Cornely","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib282","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/jac\/dks189","article-title":"Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: Real-life data from a single-centre institutional retrospective observational study","volume":"67","author":"Auberger","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib283","first-page":"64","article-title":"Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles","volume":"26","author":"De la Serna","year":"2013","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.cmi.2019.05.019_bib284","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","article-title":"Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole","volume":"40","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib285","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2010.04.017","article-title":"Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients","volume":"17","author":"Winston","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2019.05.019_bib286","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib287","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200203000-00015","article-title":"Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children","volume":"21","author":"Walsh","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib288","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1002\/cncr.22348","article-title":"Caspofungin Combination Therapy Study Group. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis","volume":"107","author":"Maertens","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2019.05.019_bib289","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","article-title":"Micafungin (fk463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis","volume":"53","author":"Denning","year":"2006","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2019.05.019_bib290","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-3062.2008.00349.x","article-title":"Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis","volume":"11","author":"Kontoyiannis","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib291","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1097\/MPH.0b013e318299c6bd","article-title":"Efficacy and safety of micafungin for febrile neutropenia in pediatric patients with hematological malignancies: a multicenter prospective study","volume":"35","author":"Kobayashi","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.cmi.2019.05.019_bib292","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2008.06.040","article-title":"Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis","volume":"44","author":"Goldberg","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cmi.2019.05.019_bib293","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin b for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2019.05.019_bib294","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/INF.0b013e3181da2171","article-title":"A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin b for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia","volume":"29","author":"Maertens","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib295","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2012.09156.x","article-title":"A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children","volume":"158","author":"Caselli","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2019.05.019_bib296","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: A randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib297","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2009.21.8032","article-title":"Clinically driven diagnostic antifungal approach in neutropenic patients: A prospective feasibility study","volume":"28","author":"Girmenia","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cmi.2019.05.019_bib298","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/j.ijid.2011.01.011","article-title":"Galactomannan-guided preemptive vs. Empirical antifungals in the persistently febrile neutropenic patient: A prospective randomized study","volume":"15","author":"Tan","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2019.05.019_bib299","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.12659\/MSM.897596","article-title":"Preemptive antifungal therapy for febrile neutropenic hematological malignancy patients in China","volume":"22","author":"Yuan","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.cmi.2019.05.019_bib300","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/INF.0000000000000101","article-title":"Role of management strategies in reducing mortality from invasive fungal disease in children with cancer or receiving hemopoietic stem cell transplant: A single center 30-year experience","volume":"33","author":"Castagnola","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2019.05.019_bib301","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/jac\/dky244","article-title":"Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial","volume":"73","author":"Santolaya","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.05.019_bib302","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin b for empirical therapy in patients with persistent fever and neutropenia. National institute of allergy and infectious diseases mycoses study group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2019.05.019_bib303","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin b for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2019.05.019_bib304","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/INF.0b013e318067b4d1","article-title":"Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children","volume":"26","author":"Koo","year":"2007","journal-title":"Pediatr Infect Dis J"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19302824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19302824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:23:53Z","timestamp":1761117833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19302824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":304,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1198743X19302824"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.05.019","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}